

Associate Directors Meeting MINUTES

MEETING DATE/TIME	September 13 th , 2021 / 1:00 – 2:00 pm				
EXECUTIVE OWNER	Eileen White/Anita Kinney				
EXECUTIVE NOTE TAKER	Gina Londino-Greenberg				
ATTENDEES		Present		Present	
	David August	Х	Edmund Lattime	X	
	Adam Berger	Х	Gina Londino-Greenberg	Х	
	Andrew Evens		Linda Tanzer	X	
	Shridar Ganesan		Allison Warzala		
	Howard Hochster	X	Eileen White	X	
	Yibin Kang		David Foran	X	
	Anita Kinney	X	Daniel Pearson	X	
	Haejin In	X			

AGENDA TOPIO	CS	
TOPIC	DISCUSSION/CONCLUSION	RECOMMENDATION /ACTION
Welcome to new AD, Diversity, Equity, and Inclusion	H. In was welcomed and introduced as the new AD, Diversity, Equity, and Inclusion, and given a brief description and overview of the purpose of the Associate Directors meetings.	
Urgent Issues (Team)		
Deputy Director's Report (White)		
EPIC Deployment (Foran)	Please see attached slide set. The question was raised of how Genomic Data would be linked to Patient Data. D. Foran's team actively and routinely pull data from the Foundation Medicine sequencers. They now have structured data entered into the Clinical Data Warehouse (CDW), which should now be able to be linked to patients. IRB approval is eventually coming to link somatic data and germline mutations data, but RWJBH does not want to share financial data (e.g., claims data). It was noted that there continue to be questions of data "ownership" between CINJ and RWJBH, such that additional investment by the cancer institute might be needed, to accommodate all of the future requests for RWJBH data. The integration between the university and the health system was slowed by the COVID-19 pandemic. A data sharing agreement has been put in place between Rutgers University and RWJBH system after a two-year-long process. A Patient Portal that comes with EPIC will have to be patched into the current system being used. The actual deployment of the CDW will be in April 2022. At that time, cancer researchers will be able to use it to search for available data. The CDW will be able to provide statistics on the number of biospecimens and associated data are available in the biorepository for research projects/topics. It was noted that the implementation of EPIC could lead to a slow in clinic activity. There are plans to get more staff to help in the clinics. However, it is going to be challenging going live with EPIC during the CCSG Year of Record.	D. Foran will see if he can get a copy of the Data Use Agreement to share with the ADs.
Catchment Area Dashboard (Kinney/Pearson)	A demonstration was given of the new Catchment Area Dashboard. The Community Outreach and Engagement (COE) team is responsible for providing data to assist researchers with conducting work to address the catchment area burden. Data is provided in collaboration with the Office of Human Research Services (OHRS) and the RWJBH Tumor Registry.	

Next Meeting	October 11 th at 1:00 pm	
	This dashboard defines "analytic cases" as new cases seen at each specific site, either at time of diagnosis or later on. The data does not include someone who goes for a second opinion but then does continue care at that site. It was noted that an "analytic case" often means that at least 50% of care has taken place at that site, which can be a means of preventing duplicated counting of cases (i.e., if a patient goes from one site to another for care). The Catchment Area Dashboard already has filters available to ensure no duplication of cases. Other data on the Catchment Area Dashboard comes from the CDC's Cancer Registry for the State of New Jersey. Data is also available on cancer risk factors, including several types of air pollutants. Some data may be impacted by the transition of pulling data from EPIC and the CDW rather than ONCORE. The registrars might need training on how to ask about race and gender identifications. The COE team can provide support to researchers in understanding and comparing the available data. The R Studio platform that supports the dashboard allows for reports to be generated and downloaded. The Associate Directors are invited to send recommendations for enhancing the reports available. This dashboard is available via the CINJ Intranet. The COE team meets with each DSG to discuss where they are with minority enrollments into clinical trials. It was noted that at a future AD meeting, the priority cancers might need to be updated. It would also be advisable to add a separate page on the Catchment Area Dashboard relating to the five priority cancers.	H. Hochster will email S. Solometo and A. Kinney about arranging a training for the registrars.